3D(6-acyl) PHAD® | CAS# 252042-59-4 | adjuvant in human vaccines

MedKoo Cat#: 412668 | Name: 3D(6-acyl) PHAD

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

3D(6-acyl) PHAD is a synthetic monophosphoryl Lipid A available for use as an adjuvant in human vaccines.

Chemical Structure

3D(6-acyl) PHAD

CAS#252042-59-4

Theoretical Analysis

MedKoo Cat#: 412668

Name: 3D(6-acyl) PHAD

CAS#: 252042-59-4

Chemical Formula: C96H184N3O21P

Exact Mass: 0.0000

Molecular Weight: 1747.50

Elemental Analysis: C, 65.98; H, 10.61; N, 2.40; O, 19.23; P, 1.77

Price and Availability

Size	Price	Availability	Quantity
1mg	USD 550.00	2 Weeks
5mg	USD 1,650.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

3D(6-acyl) PHAD; Monophosphoryl Hexa-acyl Lipid A, 3-Deacyl

IUPAC/Chemical Name

ammonium (2R,3S,4R,5R,6R)-2-(hydroxymethyl)-5-((R)-3-(tetradecanoyloxy)tetradecanamido)-4-(((R)-3-(tetradecanoyloxy)tetradecanoyl)oxy)-6-(((2R,3S,4R,5R,6S)-3,4,6-trihydroxy-5-((R)-3-(tetradecanoyloxy)tetradecanamido)tetrahydro-2H-pyran-2-yl)methoxy)tetrahydro-2H-pyran-3-yl hydrogen phosphate

InChi Key

BKGJOWVNLQLVQX-ZLHZNJIMSA-N

InChi Code

InChI=1S/C96H181N2O21P.H3N/c1-7-13-19-25-31-37-40-46-52-58-64-70-85(102)113-78(67-61-55-49-43-34-28-22-16-10-4)73-83(100)97-89-92(107)91(106)82(116-95(89)108)77-112-96-90(98-84(101)74-79(68-62-56-50-44-35-29-23-17-11-5)114-86(103)71-65-59-53-47-41-38-32-26-20-14-8-2)94(93(81(76-99)117-96)119-120(109,110)111)118-88(105)75-80(69-63-57-51-45-36-30-24-18-12-6)115-87(104)72-66-60-54-48-42-39-33-27-21-15-9-3;/h78-82,89-96,99,106-108H,7-77H2,1-6H3,(H,97,100)(H,98,101)(H2,109,110,111);1H3/t78-,79-,80-,81-,82-,89-,90-,91-,92-,93-,94-,95+,96-;/m1./s1

SMILES Code

O[C@H]([C@@H](CO[C@@H]([C@@H]1NC(C[C@H](OC(CCCCCCCCCCCCC)=O)CCCCCCCCCCC)=O)O[C@H](CO)[C@@H](OP([O-])(O)=O)[C@@H]1OC(C[C@H](OC(CCCCCCCCCCCCC)=O)CCCCCCCCCCC)=O)O[C@H](O)[C@@H]2NC(C[C@H](OC(CCCCCCCCCCCCC)=O)CCCCCCCCCCC)=O)[C@@H]2O.[NH4+]

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 1,747.50 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Lederhofer J, van Lent J, Bhoelan F, Karneva Z, de Haan A, Wilschut JC, Stegmann T. Development of a Virosomal RSV Vaccine Containing 3D-PHAD® Adjuvant: Formulation, Composition, and Long-Term Stability. Pharm Res. 2018 Jul 3;35(9):172. doi: 10.1007/s11095-018-2453-y. PMID: 29971500; PMCID: PMC6061504. 2: Taleghani N, Bozorg A, Azimi A, Zamani H. Immunogenicity of HPV and HBV vaccines: adjuvanticity of synthetic analogs of monophosphoryl lipid A combined with aluminum hydroxide. APMIS. 2019 Mar;127(3):150-157. doi: 10.1111/apm.12927. PMID: 30746792. 3: Hernandez A, Patil NK, Stothers CL, Luan L, McBride MA, Owen AM, Burelbach KR, Williams DL, Sherwood ER, Bohannon JK. Immunobiology and application of toll-like receptor 4 agonists to augment host resistance to infection. Pharmacol Res. 2019 Dec;150:104502. doi: 10.1016/j.phrs.2019.104502. Epub 2019 Nov 2. PMID: 31689522; PMCID: PMC6884699. 4: Cawlfield A, Genito CJ, Beck Z, Bergmann-Leitner ES, Bitzer AA, Soto K, Zou X, Hadiwidjojo SH, Gerbasi RV, Mullins AB, Noe A, Waters NC, Alving CR, Matyas GR, Dutta S. Safety, toxicity and immunogenicity of a malaria vaccine based on the circumsporozoite protein (FMP013) with the adjuvant army liposome formulation containing QS21 (ALFQ). Vaccine. 2019 Jun 27;37(29):3793-3803. doi: 10.1016/j.vaccine.2019.05.059. Epub 2019 May 28. PMID: 31151801. 5: Singh P, Beck Z, Matyas GR, Alving CR. Saturated phospholipids are required for nano- to micron-size transformation of cholesterol-containing liposomes upon QS21 addition. J Liposome Res. 2019 Sep;29(3):247-250. doi: 10.1080/08982104.2018.1538239. Epub 2018 Nov 23. PMID: 30350748. 6: Genito CJ, Beck Z, Phares TW, Kalle F, Limbach KJ, Stefaniak ME, Patterson NB, Bergmann-Leitner ES, Waters NC, Matyas GR, Alving CR, Dutta S. Liposomes containing monophosphoryl lipid A and QS-21 serve as an effective adjuvant for soluble circumsporozoite protein malaria vaccine FMP013. Vaccine. 2017 Jul 5;35(31):3865-3874. doi: 10.1016/j.vaccine.2017.05.070. Epub 2017 Jun 7. PMID: 28596090.